ScholarIQanswers from OpenAlex & ORCID
João Pedro Ferreira
ResearcherPublications, citations & collaboration network
João Pedro Ferreira is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does João Pedro Ferreira have?
ScholarIQindexed works
João Pedro Ferreira has 584 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does João Pedro Ferreira have?
ScholarIQcitation count
João Pedro Ferreira has 22,063 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of João Pedro Ferreira?
ScholarIQh-index
João Pedro Ferreira has an h-index of 65 in OpenAlex.
What is the i10-index of João Pedro Ferreira?
ScholarIQi10-index
João Pedro Ferreira has an i10-index of 288 in OpenAlex.
What is the ORCID of João Pedro Ferreira?
ScholarIQorcid
The ORCID for João Pedro Ferreira is on the source record.
What is the OpenAlex record for João Pedro Ferreira?
ScholarIQopenalex
The OpenAlex for João Pedro Ferreira is on the source record.
What are the most-cited papers on João Pedro Ferreira?
ScholarIQmost cited works
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Juan Esteban Gómez‐Mesa, Stefan Janssens, James L. Januzzi, José Ramón González‐Juanatey, Béla Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr Ponikowski, Michele Senni, David Sim, Jindřich Špinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragoş Vinereanu, Jian Zhang, Peter E. Carson, Carolyn S.P. Lam, Nikolaus Marx, Cordula Zeller, Naveed Sattar, Waheed Jamal, Sven Schnaidt, Janet Schnee, Martina Brueckmann, Stuart Pocock, Faı̈ez Zannad, Milton Packer
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Faı̈ez Zannad, João Pedro Ferreira, Stuart Pocock, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal, Milton Packer
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Adriaan A. Voors, Christiane E. Angermann, John R. Teerlink, Sean P. Collins, Mikhail Kosiborod, Jan Biegus, João Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka, Jasper Tromp, C. Jan Willem Borleffs, Changsheng Ma, J COMINCOLET, Michael Fu, Stefan Janssens, Róbert Gábor Kiss, Robert J. Mentz, Yasushi Sakata, Henrik Schirmer, Morten Schou, P. Christian Schulze, Lenka Špinarová, Maurizio Volterrani, Jerzy Krzysztof Wranicz, Uwe Zeymer, Shelley Zieroth, Martina Brueckmann, Jon Blatchford, Afshin Salsali, Piotr Ponikowski
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
Muthiah Vaduganathan, Brian Claggett, Pardeep S. Jhund, Jonathan W. Cunningham, João Pedro Ferreira, Faı̈ez Zannad, Milton Packer, Gregg C. Fonarow, John J.V. McMurray, Scott D. Solomon
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart Pocock, Peter E. Carson, Inder S. Anand, Wolfram Doehner, Markus Haass, Michel Komajda, Alan B. Miller, Steen Pehrson, John R. Teerlink, Martina Brueckmann, Waheed Jamal, Cordula Zeller, Sven Schnaidt, Faı̈ez Zannad